|
|
|
|
|
12.08.25 - 14:03
|
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire)
|
|
|
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William S. Solari III to its Board of Directors.
Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President and CEO of CareDx, Inc., guiding the company through a period of rapid growth. He served as Chief Operating Officer at Ardelyx, where he built international partnerships to support commercialization, and held senior leadership roles at AstraZeneca, where he completed over 100 biologics transactions and managed portfolio strategy for more than 150 assets. His earlier career includes McKinsey & Company, Boehringer Ingelheim, and Organon.
Mr. Solari brings over 30 years of legal and financial experience in corporate gov...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.25 - 23:03
|
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire)
|
|
|
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan.
Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands.
“Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx,” said John Hanna, CEO of CareDx. “His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase.”
In co...
|
|
|
23.07.25 - 13:09
|
CareDx to Report Second Quarter 2025 Financial Results (Business Wire)
|
|
|
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Individuals interested in listening to the conference call may do so by dialing 1-800-274-8461 for domestic callers or 1-203-518-9814 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please visit the Events & Presentations section of CareDx's Investor Relations website at: investors.caredx.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, de...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.06.25 - 22:36
|
CareDx Announces Repurchase of 5% of Outstanding Shares (Business Wire)
|
|
|
Board of Directors Authorizes New $50 Million Share Repurchase ProgramBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares.
The share repurchase follows the completion of the company's seventh consecutive quarter of testing services volume growth and a first-quarter total revenue of $84.7 million, representing 18% year-over-year growth. CareDx ended the first quarter with $231 million in cash, cash equivalents, marketable securities, and no debt.
“The investments we have made in our commercial organization and operational infrastructure are translating into growth. We saw a clear opportunity to return value to our shareholde...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
